METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Clinical trials for METASTATIC TRIPLE-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC TRIPLE-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat breast cancer
Disease control OngoingThis phase II study tests a combination of four drugs (trilaciclib, pembrolizumab, gemcitabine, and carboplatin) in people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. The main goals are to see how well the treatment shrinks tumors …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 17, 2026 03:16 UTC
-
New hope for Hard-to-Treat breast cancer: drug shows promise in chinese trial
Disease control OngoingThis study tests a drug called sacituzumab govitecan in 80 Chinese patients with metastatic triple-negative breast cancer who have already tried at least two other treatments. The main goal is to see how many patients' tumors shrink or disappear. This is an advanced cancer that i…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New hope for aggressive breast cancer: drug duo plus chemo shows promise
Disease control OngoingThis study tests whether adding two experimental drugs (AK117 and AK112) to standard chemotherapy can shrink tumors in people with advanced triple-negative breast cancer that hasn't been treated before. About 120 participants will receive the combination and be monitored for resp…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New combo therapy shows promise for Hard-to-Treat breast cancer
Disease control OngoingThis study tested whether adding another targeted drug (ceralasertib or adavosertib) to the standard drug olaparib works better than olaparib alone for people with metastatic triple-negative breast cancer. The trial included 273 adults whose tumors had specific gene changes affec…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC